Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novel Mechanism for Activation of SIRT1

Published: Wednesday, April 24, 2013
Last Updated: Wednesday, April 24, 2013
Bookmark and Share
Assay format allows for simple, sensitive detection of sirtuin activity on any desired substrate.

Merck Millipore has introduced the SIRTainty™ Class III HDAC assay which allows for simple, sensitive detection of sirtuin activity on any desired substrate.

The assay utilizes a novel patent-pending technology for the sensitive detection of all known sirtuin family members.

Unlike conventional assays that are dependent upon a single pre-labeled fluorescently tagged substrate, the SIRTainty™ Class III HDAC assay employs untagged acetylated peptide substrates.

This approach not only enables unparalleled flexibility in the choice of sirtuin isoform and peptide substrate, but also eliminates the potential for artifacts due to the use of artificial substrates containing bulky fluorophores.

A recent report published in the March 8th issue of Science (Hubbard et al. 2013) from the lab of David Sinclair, Ph.D., Harvard Medical School, described a novel mechanism for the allosteric activation of SIRT1 by small molecules.

In order to perform this work, the authors employed the SIRTainty™ assay to measure SIRT1 deacetylation of native peptide substrates.

"The SIRTainty™ assay is a superior assay for measuring sirtuin activity," said David Sinclair, Ph.D., corresponding author and co-inventor of the SIRTainty™ assay. "Unlike other HDAC assays that limit flexibility in experimental design, there is no fluorophore on the substrate. Any native substrate can be tested."

Sirtuins are a class of enzyme that removes acetyl groups from a variety of proteins that play key roles in multiple biological processes.

These enzymes, also known as class III HDAC (histone deacetylases), have been implicated in a variety of age-related diseases such as cancer, Alzheimer's disease and Type 2 diabetes. Sirtuins have emerged as key targets for drug development.

"The ability to measure SIRT1 deacetylation using fluorophore-free peptides derived from physiological substrates was critical in enabling our mechanistic analysis of SIRT1 activation," noted Basil P. Hubbard, Ph.D., lead author of the article and co-inventor of the SIRTainty™ assay.

Hubbard continued, "The SIRTainty™ assay is amenable to the biochemical study of multiple mammalian sirtuin deacetylases and their homologs in lower organisms. Because of this, it has the potential to facilitate the discovery and characterization of small-molecule modulators of other sirtuins."

Resveratrol, a compound found in red wine, has been shown to activate SIRT1 in vivo. However, there is controversy in the field as to whether the effect of Resveratrol on SIRT1 is direct.

Previously it was shown that although Resveratrol was capable of activating SIRT1 deacetylation of a fluorescently-tagged substrate in vitro, it was unable to do so using the corresponding non-tagged peptide.

However, by using the technology now offered in the SIRTainty™ assay, the team of Harvard researchers showed that Resveratrol and synthetic SIRT1 activators can directly enhance SIRT1 deacetylation in vitro using natural amino acid substrates and SIRT1 targets containing specific hydrophobic motifs.

Their work suggests that the metabolic benefits of Resveratrol are due to direct activation of SIRT1 enzymatic activity.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Enters Into Strategic Alliance with Turgut Ilaç
Company to provide Provantage® End-to-End solution for development and manufacture of biosimilars.
Friday, October 23, 2015
Merck Millipore Introduces Enhancements to its EMPROVE® Program
Instant, online access to regulatory and technical information on portfolio of 400 products.
Thursday, September 17, 2015
Merck Millipore Enters Into Agreement with Singulex
Acquiring exclusive worldwide rights to Singulex’s SMC™ technology - instruments, assays and services - for research applications.
Thursday, May 28, 2015
Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Invests €12M in France Facility
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.
Tuesday, August 12, 2014
Princeton’s Dr Bonnie Bassler Receives 2014 Alice C. Evans Award
Merck Millipore congratulates winner of the Alice C. Evans award for leadership in clinical microbiology.
Thursday, May 22, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore, VWR Extend Western European Distribution Agreement
Provides VWR access to more Merck Millipore products and reagents for chemical and microbiological analysis.
Wednesday, April 09, 2014
Merck Millipore Introduces the Lab Solutions Virtual Conference: “Complete Solutions for Food Safety Analysis.”
Merck Millipore, the Life Science division of Merck KGaA has announced the first Lab Solutions Virtual Conference on November 19 and 20, 2013.
Tuesday, November 05, 2013
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Merck Millipore Partners with Gyros
Partnership to develop, manufacture and commercialize kits on the Gyrolab™ immunoassay platform.
Tuesday, July 16, 2013
Merck Millipore Opens New R&D Center
Facility fosters company's focus on Bioavailability Enhancement.
Monday, July 15, 2013
Merck Millipore Introduces the Lab Water Virtual Conference
“The Lab of Tomorrow, Bringing the Future to Life Today”.
Wednesday, May 22, 2013
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!